Quetiapine extended release: In schizophrenia

CNS Drugs

Volumn 23, Issue 3, 2009, Pages 261-269

  Baldwin, Claudine M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; LITHIUM; OLANZAPINE; PHENYTOIN; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; VALPROATE SEMISODIUM;

ADJUVANT THERAPY; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; BIPOLAR I DISORDER; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART RATE; HUMAN; HYPERGLYCEMIA; INCIDENCE; LEUKOPENIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT DURATION; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; VITAL SIGN; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 63149184835     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923030-00007     Document Type: Review

References (22)

1. National Institute for Clinical Excellence. Schizophrenia: full national clinical guideline on core interventions in primary and secondary care [online]. Available from URL: http:// www.nice.org.uk/nicemedia/pdf/cg001fullguideline. pdf [Accessed 2009 Feb 10]
2. Kastrup MC, Baez-Ramos A. Global mental health. Dan Med Bull 2007; 54 (1): 42-3
3. Basar E, Guntekin B. A review of brain oscillations in cognitive disorders and the role of neurotransmitters. Brain Res 2008; 1235: 172-93
4. Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psych 2009 Mar 17; 33 (17): 199-204
5. Gunasekara NS, Spencer CM. Quetiapine: a review of its use in schizophrenia. CNS Drugs 1998; 9 (4): 325-40
6. Cheer SM, Wagstaff AJ. Quetiapine: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18 (3): 173-99
7. Keating GM, Robinson DM. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs 2007; 67 (7): 1077-95
8. Medicines Evaluation Board. Public assessment report of the medicines evaluation board in the Netherlands [online]. Available from URL: http://db.cbg-meb.nl/mri/par/ nlh-0156-008-009-010-011.pdf [Accessed 2009 Feb 10]
9. AstraZeneca. Seroquel XR and Seroquel approved in Europe for new indications for the treatment of bipolar disorder [media release; online]. Available from URL: http://www.astrazeneca. com/media/latest-press-releases/ 5413?itemId=4179301 [Accessed 2009 Mar 19]
10. US FDA. Prescribing information. Seroquel XR (quetiapine fumarate) extended-release tablets [online]. Available from URL: http://www.fda.gov/cder/ foi/label/2008/ 022047s006s007s008lbl.pdf [Accessed 2009 Feb 10]
11. Electronic Medicines Compendium. Seroquel XL 50mg, 200 mg, 300 mg, 400 mg prolonged-release tablets: summary of product characteristics [online]. Available fromURL: http:// emc.medicines.org.uk/medicine/21175/SPC/Seroquel+ XL+50+mg%2c+200+mg%2c+300+mg%2c+400+mg-+prolonged-release+tablets/ [Accessed 2009 Feb 10]
12. 1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008; 33: 2303-12
13. Nyberg S, Takano A, Jucaite A, et al. PET-measured occupancy of the norepinephrine transporter by extended release quetiapine fumarate in brains of healthy subjects [abstract no. NR5-126]. 161stAnnualMeeting of theAmerican Psychiatric Association; 2008 May 3-8; Washington, DC
14. Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008 Jan; 69 (1): 81-6
15. Juckel G, Winter HR, Stahle L, et al. The pharmacokinetics of extended release quetiapine fumarate are not affected by a light meal [poster]. 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; 2008 Feb 3-7; Montreux
16. Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients [online]. Available fromURL: http:// www.psychiatrymmc.com/category/archived-issues/ 11-2007-november-2007/ [Accessed 2009 Feb 23]
17. Moller HJ, Johnson S, Mateva T, et al. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol 2008 Mar; 23 (2): 95-105
18. Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007 Jun; 68 (6): 832-42
19. Lindenmayer J, Brown D, Liu S, et al. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull 2008; 41 (3): 11-35
20. Meulien D, Brecher M, Huizar K. Once-daily extended release quetiapine fumarate (quetiapineXR): pooled safety data from 3 placebo-controlled monotherapy studies in acute schizophrenia [abstract no. P0174]. Eur Psych 2008; 23 Suppl.: S132
21. AstraZeneca. A 6-week, multicenter, double-blind, double-dummy, randomized comparison of the efficacy and safety of sustained-release formulation quetiapine fumarate (seroquel ™) and placebo in the treatment of acutely ill patients with schizophrenia [online]. Available from URL: http://www.astrazenecaclinicaltrials. com/-mshost2715844/content/content/ resources/media/2958892/d1444c00133.pdf [Accessed 2009 Feb 10]
22. Ganesan S, Agambaram V, Randeree F, et al. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008 Jan; 24 (1): 21-32